OBF1 Antibody

What is OBF1 and why is it important in immunological research?

OBF1 (also known as BOB1, OCAB, or POU2AF1) is a 256-amino acid transcriptional coactivator that specifically associates with either POU2F1/OCT1 or POU2F2/OCT2 transcription factors. It functions as a B-cell-specific coactivator that boosts POU2F1/OCT1 mediated promoter activity and, to a lesser extent, POU2F2/OCT2 activity . The protein is localized to the nucleus and features ubiquitinated post-translational modifications .

OBF1 is essential for the response of B-cells to antigens and required for the formation of germinal centers, making it a critical target in immunological research focused on antibody production and B-cell development . Understanding OBF1 function provides insights into fundamental B-cell biology and potential therapeutic targets for immunological disorders.

What are the common applications for OBF1 antibodies in research settings?

OBF1 antibodies are primarily utilized for antigen-specific immunodetection in biological samples across several experimental techniques :

• Western Blot (WB): The most common application, used to detect OBF1 protein expression levels and molecular weight in cell or tissue lysates.

• Enzyme-Linked Immunosorbent Assay (ELISA): Particularly peptide ELISA formats for quantitative detection of OBF1.

• Immunohistochemistry (IHC): For visualizing OBF1 expression patterns in tissue sections, especially useful for studying B-cell distribution in lymphoid tissues.

These applications enable researchers to investigate OBF1 expression patterns, protein-protein interactions, and functional roles in normal and pathological conditions .

How should researchers select the appropriate OBF1 antibody for their experimental needs?

When selecting an OBF1 antibody, researchers should consider several critical parameters:

• Species reactivity: Available antibodies demonstrate reactivity with human (Hu), mouse (Ms), rat (Rt), bovine (Bv), and dog (Dg) OBF1, so select based on your experimental model .

• Antibody format:

  • Unconjugated antibodies for flexible detection methods

  • Conjugated antibodies (such as HRP-conjugated or fluorophore-conjugated like Alexa Fluor 555) for direct detection without secondary antibodies

• Clonality:

  • Polyclonal antibodies for higher sensitivity

  • Monoclonal antibodies (like SP92 clone) for higher specificity and reproducibility

• Validated applications: Ensure the antibody has been validated for your specific application through quality control methods that evaluate binding affinity and efficiency of antibody labeling post-conjugation .

• Antibody origin: Consider using recombinant monoclonal antibodies for higher batch-to-batch consistency in long-term studies .

How can researchers effectively analyze OBF1 expression patterns in antibody-secreting cell differentiation?

Analysis of OBF1 expression during antibody-secreting cell (ASC) differentiation requires a sophisticated experimental approach due to OBF1's complex role in this process . An effective methodological framework includes:

• Cell isolation and culture system:

  • Isolate resting B cells using magnetic or flow cytometry-based separation

  • Culture with appropriate stimuli (CD40L/IL-4 for T cell-dependent conditions or LPS for T cell-independent conditions)

  • Use cell division tracking dyes like CFSE to monitor proliferation alongside differentiation

• ASC identification strategy:

  • Employ Syndecan-1 (CD138) as a reliable ASC marker in CD40L/IL-4 cultures

  • Confirm ASC identity through functional antibody secretion assays

  • Sort cells based on Syndecan-1 expression levels (low, intermediate, high) to analyze differentiation stages

• OBF1 detection protocol:

  • Use validated anti-OBF1 antibodies for immunoblotting or immunofluorescence

  • For quantitative analysis, combine with flow cytometry to correlate OBF1 expression with differentiation markers

  • Consider using complementary techniques (RT-PCR, immunoblotting) to validate protein expression findings

This comprehensive approach allows researchers to effectively track OBF1's functional role throughout the ASC differentiation process.

What are the key considerations when interpreting contradictory data regarding OBF1's role in antibody production?

Research has revealed apparent contradictions regarding OBF1's role in antibody production that require careful interpretation . When analyzing such data, researchers should consider:

• Stimulus-dependent effects: OBF1 has divergent roles depending on stimulation conditions:

  • Required for ASC differentiation under T cell-dependent (TD) conditions (CD40L/IL-4)

  • Less critical under T cell-independent (TI) conditions (LPS stimulation)

• Isotype-specific impacts: OBF1 differentially affects immunoglobulin isotypes:

  • IgM production is relatively OBF1-independent

  • IgG1 production shows greater sensitivity to OBF1 loss

• Direct vs. indirect mechanisms: Distinguish between:

  • OBF1's indirect effects on antibody production through regulation of ASC differentiation

  • Minor direct effects on immunoglobulin gene expression

• Temporal staging: Consider OBF1's dual roles during ASC differentiation:

  • Early repression of T cell-dependent differentiation

  • Critical promotion of final ASC differentiation stages

• Gene regulatory networks: Examine interactions with other transcription factors:

  • OBF1 loss prevents proper Blimp-1/prdm1 induction

  • Failed repression of bcl-6, Pax5, and AID in OBF1-null cells

When faced with contradictory data, these factors should be systematically evaluated to determine which mechanism predominates under the specific experimental conditions being tested.

How can researchers effectively use OBF1 antibodies to study transcriptional regulatory mechanisms?

To effectively investigate OBF1's transcriptional regulatory mechanisms, researchers should employ a multi-faceted approach using OBF1 antibodies:

• Chromatin immunoprecipitation (ChIP) protocols:

  • Select highly specific OBF1 antibodies validated for ChIP applications

  • Optimize crosslinking conditions (typically 1% formaldehyde for 10 minutes)

  • Include controls for antibody specificity (isotype control and OBF1-deficient cells)

  • Analyze binding to known targets like PORE sequences in the Osteopontin enhancer

• Co-immunoprecipitation (Co-IP) strategy:

  • Use antibodies against OBF1 to precipitate protein complexes

  • Detect interactions with POU domain transcription factors (OCT1/POU2F1 or OCT2/POU2F2)

  • Analyze configuration-dependent interactions (PORE vs. MORE sequence arrangements)

• In vitro transcription assays:

  • Employ reporter constructs containing OBF1-responsive elements

  • Compare PORE vs. MORE sequence configurations to assess OBF1 accessibility

  • Analyze how OBF1 enhances transcriptional potential of Oct1 in different promoter contexts

This methodological approach allows comprehensive investigation of OBF1's role in transcriptional regulation and its configuration-dependent interactions with POU transcription factors.

What are the optimal protocols for detecting OBF1 in B-cell subpopulations using immunofluorescence?

For optimal detection of OBF1 in B-cell subpopulations using immunofluorescence, the following protocol is recommended:

• Sample preparation:

  • For tissue sections: Fix in 4% paraformaldehyde, embed in paraffin or freeze in OCT compound

  • For cell suspensions: Fix cells in 2% paraformaldehyde, permeabilize with 0.1% Triton X-100

  • Block with 5% normal serum corresponding to secondary antibody species

• Antibody selection and dilution:

  • Primary: Use directly conjugated antibodies like Alexa Fluor 555-conjugated anti-BOB1 antibody (clone SP92) for direct detection

  • Alternative approach: Use unconjugated primary antibody followed by fluorophore-conjugated secondary

  • Optimal dilution: Typically 1:100 to 1:500 (determined through titration experiments)

• Co-staining strategy:

  • B-cell markers: CD19 or CD20 for general B-cell identification

  • Differentiation markers: Pair with Syndecan-1 (CD138) to distinguish ASCs

  • Nuclear markers: Include DAPI for nuclear localization confirmation

• Controls:

  • Positive control: Germinal center B cells (high OBF1 expression)

  • Negative control: T cells (minimal OBF1 expression)

  • Technical control: Secondary antibody only

• Imaging parameters:

  • Capture Z-stacks to ensure complete nuclear visualization

  • Use sequential scanning to prevent fluorophore crosstalk

  • Employ consistent exposure settings for quantitative comparisons

This protocol enables precise subcellular localization and quantification of OBF1 in different B-cell subpopulations.

What techniques should be employed to validate OBF1 antibody specificity for research applications?

Validating OBF1 antibody specificity is critical for ensuring reliable experimental results. A comprehensive validation strategy should include:

• Genetic validation:

  • Test antibody reactivity in OBF1-null (OBF-1⁻/⁻) cells or tissues

  • Use siRNA or CRISPR-mediated knockdown to create transient depletion controls

  • Verify signal reduction or elimination in these negative controls

• Expression system validation:

  • Perform overexpression studies using OBF1 cDNA to create positive controls

  • Use retroviral complementation of OBF1-null cells as demonstrated in previous studies

  • Confirm signal increase corresponding to expression levels

• Peptide competition assays:

  • Pre-incubate antibody with immunizing peptide or recombinant OBF1

  • Verify signal reduction in subsequent detection assays

  • Include gradient of competing peptide concentrations

• Cross-reactivity assessment:

  • Test antibody against related POU domain-interacting proteins

  • Verify species-specificity claims across human, mouse, rat, bovine, and dog samples

  • Confirm reactivity in appropriate tissue types (B-cell specific expression)

• Application-specific validation:

  • For each experimental method (WB, ELISA, IHC), perform specific controls

  • For Western blot: Verify single band at expected molecular weight (~256 amino acids)

  • For IHC/IF: Confirm nuclear localization pattern in B cells

These validation steps ensure antibody specificity and reliability across different experimental applications.

How can researchers optimize Western blot protocols for OBF1 detection in primary B cells?

Optimizing Western blot protocols for OBF1 detection in primary B cells requires careful attention to several critical factors:

• Sample preparation optimization:

  • Lyse cells in RIPA buffer supplemented with protease inhibitors

  • Include phosphatase inhibitors to preserve post-translational modifications

  • Sonicate briefly (3×10 seconds) to shear genomic DNA

  • Perform nuclear fractionation to enrich for OBF1 (nuclear protein)

• Gel electrophoresis parameters:

  • Use 10-12% polyacrylamide gels for optimal resolution

  • Load 20-30 μg protein per lane for primary B cells

  • Include molecular weight markers spanning 25-75 kDa range

  • Run at constant voltage (100V) through stacking gel, then 150V through resolving gel

• Transfer and blocking conditions:

  • Transfer to PVDF membrane (better protein retention than nitrocellulose)

  • Use 350 mA constant current for 60-90 minutes in cold transfer buffer

  • Block with 5% non-fat dry milk in TBST for 1 hour at room temperature

• Antibody selection and dilution:

  • Primary: Use unconjugated anti-OBF1/BOB1 antibodies at 1:1000 dilution

  • Secondary: HRP-conjugated antibody at 1:5000 dilution

  • Incubate primary antibody overnight at 4°C for improved signal-to-noise ratio

• Detection strategy:

  • Use enhanced chemiluminescence (ECL) detection system

  • For quantitative analysis, consider fluorescent secondary antibodies

  • Include loading control (β-actin or GAPDH for whole cell lysates; lamin for nuclear fractions)

• Troubleshooting common issues:

  • High background: Increase blocking time or detergent concentration

  • Weak signal: Increase protein load or antibody concentration

  • Multiple bands: Try different antibody clone or optimize lysis conditions

This optimized protocol ensures reliable detection of OBF1 in primary B cell samples for quantitative analysis of expression levels.

How can OBF1 antibodies be used to investigate B-cell differentiation defects in immunological disorders?

OBF1 antibodies provide valuable tools for investigating B-cell differentiation defects in immunological disorders through several methodological approaches:

• Diagnostic immunophenotyping:

  • Use flow cytometry with anti-OBF1 antibodies to analyze nuclear expression in patient B-cell subsets

  • Compare OBF1 expression patterns between healthy controls and disease samples

  • Correlate expression with Syndecan-1 levels to assess antibody-secreting cell differentiation potential

• Functional differentiation assays:

  • Culture patient B cells with CD40L/IL-4 (T cell-dependent) or LPS (T cell-independent) stimuli

  • Track OBF1 expression during differentiation using immunoblotting or flow cytometry

  • Assess whether abnormal differentiation correlates with altered OBF1 expression or function

• Gene regulatory network analysis:

  • Examine relationship between OBF1 and other key regulators (Blimp-1, Bcl-6, Pax5)

  • Use ChIP with OBF1 antibodies to assess promoter binding activity in patient samples

  • Determine if dysregulation occurs at transcriptional cofactor level

• Immunohistochemical tissue analysis:

  • Perform dual staining with OBF1 and B-cell markers in lymphoid tissue biopsies

  • Assess germinal center architecture and OBF1 expression patterns

  • Compare nodular vs. diffuse distribution in different disease states

These approaches enable researchers to determine whether OBF1 dysfunction contributes to B-cell differentiation defects in specific immunological disorders.

What experimental approaches should be used to study the relationship between OBF1 and antibody isotype switching?

Research has revealed complex relationships between OBF1 and antibody isotype switching that require sophisticated experimental approaches to investigate :

• In vitro class switch recombination (CSR) assays:

  • Culture primary B cells with appropriate stimuli:

    • Anti-CD40 + IL-4 for IgG1 switching

    • LPS + TGF-β for IgA switching

    • LPS + IFN-γ for IgG2a switching

  • Track switching efficiency in wildtype vs. OBF1-deficient cells

  • Use flow cytometry with isotype-specific antibodies to quantify switching

• Molecular analysis of switch recombination:

  • Perform RT-PCR to detect germline transcripts (GLTs) and post-switch transcripts

  • Use digestion-circularization PCR (DC-PCR) to detect specific switch recombination events

  • Investigate AID expression and regulation in the presence/absence of OBF1

• Chromatin accessibility studies:

  • Use ChIP with OBF1 antibodies to assess binding at switch regions

  • Perform ATAC-seq to examine chromatin accessibility at Ig loci

  • Investigate histone modifications associated with switch region accessibility

• Mechanistic rescue experiments:

  • Perform retroviral complementation of OBF1-null B cells with wild-type or mutant OBF1

  • Quantify restoration of isotype switching capacity, particularly for IgG1

  • Compare relative rescue efficiency for different isotypes

• Analysis of 3' IgH enhancer activity:

  • Use reporter assays to assess OBF1's influence on 3' IgH enhancer function

  • Compare enhancer activity for different isotype promoters

  • Determine whether OBF1 requirements differ between switched and unswitched loci

This comprehensive experimental approach allows researchers to dissect OBF1's distinct roles in antibody isotype switching mechanisms.

How can immunoprecipitation with OBF1 antibodies facilitate the investigation of protein-protein interactions in B-cell transcriptional regulation?

Immunoprecipitation (IP) with OBF1 antibodies is a powerful technique for investigating protein-protein interactions in B-cell transcriptional regulation. The following methodological framework optimizes this approach:

• Sample preparation strategy:

  • Use gentle lysis buffers (150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0) to preserve protein complexes

  • Add protease inhibitors, phosphatase inhibitors, and DNase treatment

  • For nuclear proteins, perform nuclear extraction before IP

  • Pre-clear lysates with protein A/G beads to reduce background

• IP protocol optimization:

  • Select antibodies with validated IP performance (typically 2-5 μg per sample)

  • Incubate antibody with lysate overnight at 4°C with gentle rotation

  • Capture complexes using protein A/G magnetic beads for improved recovery

  • Include appropriate controls (isotype antibody, OBF1-deficient cells)

• Analysis of interacting partners:

  • Identify known interactions with POU domain proteins (OCT1/POU2F1 or OCT2/POU2F2)

  • Investigate DNA-dependency of interactions (with/without DNase treatment)

  • Examine configuration-specific interactions (PORE vs. MORE sequence arrangements)

  • Use mass spectrometry for unbiased identification of novel binding partners

• Validation and functional assessment:

  • Confirm interactions with reverse IP (IP known partners, detect OBF1)

  • Perform proximity ligation assay (PLA) for in situ visualization of interactions

  • Use sequential ChIP (ChIP-reChIP) to confirm co-occupancy at genomic targets

  • Correlate interaction data with transcriptional outcomes (e.g., Osteopontin expression)

This comprehensive IP approach enables detailed investigation of OBF1's role in protein complexes that regulate B-cell transcription.

What are the most common technical challenges when using OBF1 antibodies and how can they be addressed?

Researchers working with OBF1 antibodies frequently encounter several technical challenges. Here are the most common issues and recommended solutions:

• Nuclear protein detection difficulties:

  • Challenge: OBF1 is a nuclear protein with ubiquitinated post-translational modifications

  • Solution: Optimize nuclear extraction protocols using high-salt buffers (>300 mM NaCl) and include deubiquitinase inhibitors like N-ethylmaleimide

• Antibody specificity concerns:

  • Challenge: Multiple aliases (BOB1, OCAB, OBF-1, POU2AF1) create confusion about antibody targets

  • Solution: Verify antibody specificity using OBF1-null cells or knockdown controls and confirm recognition of the correct molecular weight target

• Fixation-sensitive epitopes:

  • Challenge: Some OBF1 epitopes are sensitive to overfixation in IHC/IF applications

  • Solution: Optimize fixation conditions (typically 10 minutes in 4% PFA) and consider antigen retrieval methods (citrate buffer, pH 6.0)

• Low abundance in certain B-cell subsets:

  • Challenge: OBF1 expression varies across B-cell differentiation stages

  • Solution: Enrich for positive cell populations where possible and use signal amplification systems (tyramide signal amplification or QDot conjugates)

• Cross-reactivity with related proteins:

  • Challenge: Potential cross-reactivity with other POU domain-interacting proteins

  • Solution: Use monoclonal antibodies with validated specificity like the SP92 clone

• Isotype-specific detection issues:

  • Challenge: Different sensitivity when measuring IgM vs. IgG in OBF1 studies

  • Solution: Calibrate detection methods specifically for each isotype and include appropriate controls

Addressing these challenges through optimized protocols ensures reliable results when working with OBF1 antibodies.

How can researchers optimize immunoprecipitation-based techniques for studying OBF1 and its interacting partners?

To optimize immunoprecipitation (IP) techniques for studying OBF1 and its interacting partners, researchers should implement this detailed protocol:

• Buffer optimization framework:

  • Standard IP: 150 mM NaCl, 1% NP-40, 50 mM Tris pH 8.0, protease inhibitors

  • Stringent conditions: Increase NaCl to 300 mM to reduce non-specific interactions

  • Gentle conditions: Reduce detergent to 0.5% NP-40 to preserve weak interactions

  • Nuclear complex preservation: Add 5 mM MgCl₂ and 0.2% Triton X-100

• Antibody selection strategy:

  • Choose antibodies validated specifically for IP applications

  • Test multiple clones if available (polyclonal for maximum capture, monoclonal for specificity)

  • Determine optimal antibody concentration through titration experiments

  • Pre-couple antibodies to beads before sample addition for improved efficiency

• Co-IP procedure optimization:

  • Pre-clear lysates with isotype-matched IgG and beads (1 hour at 4°C)

  • Incubate with specific antibody overnight at 4°C with gentle rotation

  • Include appropriate controls (isotype control, 10% input sample)

  • Wash beads 4-5 times with decreasing salt concentrations

• DNase/RNase treatment considerations:

  • Perform parallel IPs with/without nuclease treatment to distinguish direct protein interactions from DNA-mediated associations

  • Particularly important when studying transcription factor complexes like OBF1-OCT1/2

• Detection method selection:

  • Western blot for targeted detection of known/suspected partners

  • Silver staining followed by mass spectrometry for unbiased partner identification

  • Proximity-dependent biotin identification (BioID) for in vivo interaction mapping

This optimized IP framework enables robust characterization of OBF1 protein complexes in different B-cell contexts.

What quality control criteria should be applied when validating OBF1 antibodies for specific research applications?

Comprehensive quality control criteria for validating OBF1 antibodies should include:

• Specificity validation metrics:

  • Genetic controls: Test antibody in OBF1-knockout or knockdown samples

  • Peptide competition: Pre-incubation with immunizing peptide should abolish signal

  • Cross-reactivity assessment: Test against related proteins and in non-B cell types

  • Western blot profile: Verify single band at expected molecular weight

• Sensitivity determination:

  • Limit of detection: Establish minimum detectable protein concentration

  • Dynamic range: Determine linear range of signal response

  • Signal-to-noise ratio: Calculate and optimize for each application

  • Titration curve: Generate for each new antibody lot

• Application-specific validation:

  • IHC/IF: Confirm correct subcellular localization (nuclear)

  • Flow cytometry: Validate with appropriate permeabilization controls

  • ChIP: Verify enrichment at known binding sites (e.g., Osteopontin enhancer)

  • IP: Confirm pull-down of known interacting partners (OCT1/2)

• Reproducibility assessment:

  • Lot-to-lot consistency: Compare performance across manufacturing batches

  • Intra-assay variation: Multiple replicates within same experiment

  • Inter-assay variation: Compare results across different days/operators

  • Antibody stability: Test performance after freeze-thaw cycles and storage

• Functional validation:

  • Biological relevance: Confirm expected expression patterns in B-cell populations

  • Stimulation response: Verify changes in OBF1 levels with B-cell activation

  • Correlation with function: Link antibody detection to known OBF1 activities

For research applications requiring quantitative analysis, these validation criteria should be documented to ensure reliable and reproducible results across different experimental systems.